The Medicines Company to Webcast Presentation of ORION-1 Phase II Study of Inclisiran at ACC.17
March 14 2017 - 7:00AM
Business Wire
Late-breaking session featuring data from
ORION-1 study to be webcast simultaneously with presentation at
1:30 p.m. on March 17, 2017
New Time for Conference Call –
Previously-scheduled conference call/webcast to review data from
ORION-1 moved to 4:30 p.m. on March 17, 2017
The Medicines Company (NASDAQ: MDCO) today announced that
it will webcast, over the internet simultaneously with the
presentation, the detailed results from its ORION-1 Phase II study
of inclisiran, the Company’s PCSK9 synthesis inhibitor, featured in
the “Late-Breaking Clinical Trials - Featured Clinical
Research 1” session at the American College of Cardiology’s 66th
Annual Scientific Session on Friday, March 17,
2017, at 1:30 p.m., Eastern Time.
In addition, in order to ensure the availability of key outside
experts, The Medicines Company has moved the time of its
previously-scheduled conference call and webcast to review data
from the ORION-1 study to 4:30 p.m., Eastern Time, on Friday,
March 17, 2017. Among those joining the Company’s management and
inclisiran product teams for the conference call will be ORION-1’s
principal investigator, Kausik K. Ray, M.D., MPhil (Cantab), FRCP,
Professor of Public Health, Imperial College London, as well as
John J.P. Kastelein, M.D., Ph.D., Professor of Medicine and
Chairman of the Department of Vascular Medicine at
the Academic Medical Center of the University
of Amsterdam.
Webcast Information for Late-Breaking Clinical Trial
Presentations
Live audio and video of the “Late-Breaking Clinical Trials -
Featured Clinical Research 1” presentation by ORION-1’s principal
investigator, Kausik K. Ray, M.D., MPhil (Cantab), FRCP, Professor
of Public Health, Imperial College London, will be webcast over the
internet at 1:30 p.m., Eastern Time. The live webcast may be
accessed from the “Investors-Events/Presentations” section of The
Medicines Company website.
Investor Conference Call and Webcast Details
The 4:30 p.m. investor conference call may be accessed as
follows:
U.S./Canada: (877) 359-9508|International: (224)
357-2393Conference ID: 60380330
The live webcast may be accessed in the
“Investors-Events/Presentations” section of The Medicines Company
website.
A taped replay of the conference call will be archived and
available for approximately one week. The replay may be accessed as
follows:
U.S./Canada: (855) 859-2056International: (404)
537-3406Conference ID: 60380330
A replay of the webcast will also be archived and available
after the conference call.
About The Medicines Company
The Medicines Company is a biopharmaceutical company driven by
an overriding purpose – to save lives, alleviate suffering and
contribute to the economics of healthcare. The Company’s mission is
to create transformational solutions to address the most pressing
healthcare needs facing patients, physicians and providers in three
critical therapeutic areas: serious infectious disease care,
cardiovascular care and surgery and perioperative care. The Company
is headquartered in Parsippany, New Jersey, with global innovation
centers in California and Switzerland.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170314005742/en/
MediaMeg Langan,
973-290-6319Vice
Presidentmargaret.langan@themedco.comorInvestor
RelationsKrishna Gorti, M.D., 973-290-6122Vice
President, Investor Relationskrishna.gorti@themedco.com
Medicines (NASDAQ:MDCO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medicines (NASDAQ:MDCO)
Historical Stock Chart
From Apr 2023 to Apr 2024